Another combination trial, testing Opdivo with a new ADC from AbbVie

Chicago’s AbbVie and New York’s Bristol-Myers Squibb will trial a combination of Opdivo (nivolumab) and ABBV-399, an investigational antibody drug conjugate (ADC).

A Phase Ib study is underway testing tolerability and efficacy in advanced c-Met overexpressing lung cancer patients, as a second-line therapy.

ABBV-399 (telisotuzumab vedotin) is a first-in-class biologic that targets tumors which amplify or overexpress the c-Met protein.

AbbVie is sponsoring the trial. Other financial details were not disclosed.